Advia 1800 analyzer

For both, the polymorphism and gene expression studies, a standard questionnaire was used to collect medical history, physical and laboratory evaluation to phenotype the study sample. For the gene expression study participants were additionally submitted to a 2-h 75-g oral glucose tolerance test with determination of plasma glucose every 30 min.
Participants were classified as having MetS using the new International Diabetes Federation criteria [16 (link)].
Serum samples were collected for laboratory testing after a 12-h fast. Glucose levels were determined using the glucose hexokinase method (Advia 1800 analyzer, Siemens Healthcare, Munich, Germany); glycated hemoglobin (A1c), by an ion-exchange HPLC procedure (Merck-Hitachi L-9100 analyzer, Darmstadt, Germany; reference range: 28–42 mmol/mol (4.7–6.0%); and total plasma cholesterol, HDL, and triglycerides, by enzymatic colorimetric methods (Advia 1800 analyzer, Siemens Healthcare, Munich, Germany). Low-density lipoprotein cholesterol (LDL) cholesterol was calculated using the Friedewald equation.

Standard hematologic investigations were determined using the ADVIA 2110i analyzer (Roche Diagnostics GmbH, Mannheim, Germany). The concentrations of glucose, total cholesterol, triglycerides and high-density lipoprotein cholesterol (HDL) were determined using the ADVIA 1800 Siemens analyzer (Siemens Healthcare Diagnostics, Tarrytown, NY, USA). Apolipoprotein A1, B (ApoA1, ApoB) and lipoprotein (a) concentrations were determined by means of latex particle-enhanced immunonephelometric assays on the BN ProSpec nephelometer (Dade Behring, Siemens Healthcare Diagnostics, Liederbach, Germany). Insulin was measured using automated electro-chemiluminescense immunoassays (Analyzer Cobas e411, Roche Diagnostics GmbH). Insulin-like growth factor-I and insulin-like growth factor binding protein-3 were measured using automated chemiluminescence immunoassays on an IMMULITE 2000 immunoassay system (Siemens Healthcare Diagnostics Products Ltd., Frimley, Camberley, UK). Total 25-hydroxyvitamin D was measured using an automated electrochemiluminescence immunoassay on the Modular Analytics E170 analyzer. Hemoglobin A1C (HbA1C) was determined using reversed-phase cation exchange high-performance liquid chromatography on an automated glycohemoglobin analyzer HA-8160 (Arkray, Kyoto, Japan).

Standard hematological investigations were determined using the ADVIA 2110i analyzer (Roche Diagnostics GmbH, Mannheim, Germany). The concentration of glucose was determined using the ADVIA 1800 Siemens analyzer (Siemens Healthcare Diagnostics, Tarrytown, NY, USA). Insulin was measured using automated electro-chemiluminescence immunoassays (Analyzer Cobas e411, Roche Diagnostics GmbH). Hemoglobin A1c (HbA1c) was determined using reversed-phase cation exchange high-performance liquid chromatography on an automated glycohemoglobin analyzer HA-8160 (Arkray, Kyoto, Japan).
All assays were performed at the laboratories of ‘Aghia Sophia’ Children’s Hospital using the same methods and equipment during the 4-year follow-up period.
The glucose score, insulin score, Hb1Ac score, waist/hip score, and fat percentage score were defined as the mean values of these parameters throughout the study.